Q2 2024 EPS Estimates for Amedisys, Inc. (NASDAQ:AMED) Increased by Analyst

Amedisys, Inc. (NASDAQ:AMED) – Investment analysts at William Blair boosted their Q2 2024 EPS estimates for shares of Amedisys in a research report issued to clients and investors on Thursday, April 25th. William Blair analyst M. Larew now anticipates that the health services provider will post earnings of $1.18 per share for the quarter, up from their prior forecast of $1.04. The consensus estimate for Amedisys’ current full-year earnings is $4.54 per share. William Blair also issued estimates for Amedisys’ Q3 2024 earnings at $1.12 EPS and Q4 2024 earnings at $1.21 EPS.

AMED has been the subject of a number of other research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $101.00 price target on shares of Amedisys in a report on Thursday. Raymond James reaffirmed a “market perform” rating on shares of Amedisys in a research report on Tuesday, March 26th. StockNews.com began coverage on Amedisys in a report on Monday, April 8th. They issued a “buy” rating on the stock. Finally, Royal Bank of Canada lifted their target price on Amedisys from $97.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 25th. Seven equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $97.50.

Amedisys Price Performance

Shares of Amedisys stock opened at $91.16 on Friday. The company has a 50 day moving average price of $92.57 and a 200 day moving average price of $93.35. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys has a 52 week low of $73.10 and a 52 week high of $96.44.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, April 24th. The health services provider reported $1.03 EPS for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $571.41 million during the quarter, compared to analyst estimates of $565.38 million. Amedisys had a positive return on equity of 13.00% and a negative net margin of 0.91%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.00 EPS.

Institutional Investors Weigh In On Amedisys

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its holdings in Amedisys by 0.4% during the third quarter. Vanguard Group Inc. now owns 3,241,160 shares of the health services provider’s stock valued at $302,724,000 after purchasing an additional 12,137 shares in the last quarter. Alpine Associates Management Inc. raised its position in shares of Amedisys by 23.0% during the 4th quarter. Alpine Associates Management Inc. now owns 1,271,097 shares of the health services provider’s stock worth $120,830,000 after purchasing an additional 237,600 shares during the last quarter. Pentwater Capital Management LP lifted its stake in Amedisys by 239.5% in the 3rd quarter. Pentwater Capital Management LP now owns 1,144,000 shares of the health services provider’s stock valued at $106,850,000 after buying an additional 807,000 shares in the last quarter. Westchester Capital Management LLC boosted its holdings in Amedisys by 3.4% in the 4th quarter. Westchester Capital Management LLC now owns 879,402 shares of the health services provider’s stock worth $83,596,000 after buying an additional 29,016 shares during the last quarter. Finally, Park West Asset Management LLC increased its stake in Amedisys by 8.0% during the 4th quarter. Park West Asset Management LLC now owns 812,069 shares of the health services provider’s stock worth $77,195,000 after buying an additional 60,350 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.